NCT06173635 is a NA clinical trial of Maxi Move 5 in Healthy Volunteers, sponsored by Arjo AB.

Who is sponsoring NCT06173635?

NCT06173635 is sponsored by Arjo AB.

What drugs are being tested in NCT06173635?

Interventions in NCT06173635: Maxi Move 5.

What condition does NCT06173635 study?

NCT06173635 studies Healthy Volunteers.

Is NCT06173635 still recruiting?

NCT06173635 is currently completed. Last updated 14 August 2024.

Last reviewed 2024-08-14 · How we verify

NCT06173635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison Study of the Maxi Move 5 (MM5) Device

Completed NA Last updated 14 August 2024

What this trial tests

NA trial testing Maxi Move 5 in Healthy Volunteers in 21 participants. Completed in 31 May 2024.

Timeline

20 December 2023

Primary endpoint
28 February 2024

31 May 2024

Quick facts

Lead sponsor	Arjo AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	21
Start date	20 December 2023
Primary completion	28 February 2024
Estimated completion	31 May 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Maxi Move 5

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Arjo AB

Who can join

Adults 18 to 85, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to evaluate the added improvements from a caregiver and patient benefit perspective. The trial should identify the forces involved for the caregiver when manoeuvring the lift.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Arjo AB trials

Trials by the same sponsor.

NCT07213739 — A Trial to Investigate the New Caulis Pro® Low Air Loss (LAL) System · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06173635 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arjo AB
Last refreshed: 14 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06173635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing